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Abstract Sestrin-2 (SESN2) is involved in the cellular
response to different stress conditions. However, the
function of SESN2 in the cardiovascular system remains
unknown. In the present study, we tested whether
SESN2 has a beneficial effect on vascular endothelial
damage induced by angiotensin II (AngII). Firstly, we
found that AngII induces expression of SESN2 in hu-
man umbilical vein endothelial cells (HUVECs) in a
time-dependent and dose-dependent manner. We also
found that knockdown of SESN2 using small RNA
interference promotes cellular toxicity of AngII, as well
as a reduction in cell viability, exacerbation of oxidative
stress, and stimulation of apoptosis. In addition, our
results show that the c-Jun NH (2)-terminal kinase
(JNK)/c-Jun pathway is activated by AngII. Inhibiting
the activity of the JNK pathway abolishes the increase in
SESN2 induced by AngII. Importantly, overexpression
of c-Jun promotes luciferase activity of the SESN2
promoter. These findings suggest that the inductive ef-
fect of SESN2 is mediated by the JNK/c-Jun pathway.
Our results indicate that the induction of SESN2 acts as
a compensatory response to AngII for survival, imply-
ing that stimulating expression of SESN2 might be an
effective pharmacological target for the treatment of
AngII-associated cardiovascular diseases.
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Introduction
Vascular endothelial cells are involved in many aspects
of vascular biology, including blood barrier function,
clotting, angiogenesis, vasoconstriction, and vasodila-
tion (Lee et al. 2012b; Shi et al. 2013). Endothelial
dysfunction has been considered a key event involved
in the progression of several cardiovascular and non-
cardiovascular diseases (Lin et al. 2013). Oxidative
stress is known to be a main factor behind vascular
endothelial cell dysfunction (Chen et al. 2012).
Damage induced by oxidative stress is characterized
by excessive quantities of reactive oxygen species
(ROS) being generated by different sources.
Angiotensin II (AngII) is the main effector of the re-
nin–angiotensin–aldosterone system (RAAS).
Endothelial dysfunction induced by AngII has been
found to be involved in various cardiovascular diseases
including hypertension, atherosclerosis, and heart fail-
ure (Dimmeler et al. 1997). Multiple lines of evidence
have shown its function in various pro-inflammatory
actions within the vascular wall (Brasier et al. 2002;
Donnini et al. 2010). Activation of AngII signaling can
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trigger expression of pro-inflammatory adhesion mole-
cules and production of ROS, as well as induce endo-
thelial apoptosis (Sata and Fukuda 2010). However, the
use of specific antagonists of the AngII type 1 receptor
in order to block AngII signaling has been reported as an
effective way to protect the retinal vasculature against
vascular cell apoptosis resulting from hypertensive vas-
cular injury (Yang et al. 2010). Up until now, a great deal
of effort has been put into understanding the mecha-
nisms responsible for AngII’s ability to act as a mediator
of endothelial apoptosis.
Sestrins are a family of stress-inducible proteins that
are conserved across various species (Budanov et al.
2004). The gene sestrin-2 (SESN2) is an important
member in the sestrins family, which can be activated
by the transcriptional factor p53. In fact, SESN2 plays
an essential role in p53-dependent antioxidant defenses
through regeneration of peroxiredoxins from their
hyperoxidized forms and through inhibition of the target
rapamycin (TOR) complex-1 anabolic pathway
(Budanov and Karin 2008). Additionally, sestrins exhib-
it antioxidant properties in that they inhibit intracellular
reactive oxygen species (ROS). It has been shown that
SESN2 interacts with the Nrf2 suppressor Keap1, the
autophagy substrate p62, and the ubiquitin ligase Rbx1.
Notably, it has been suggested that the antioxidant func-
tion of SESN2 is mediated through activation of Nrf2 in
a manner reliant on p62-dependent autophagic degrada-
tion of Keap1 (Bae et al. 2013). Another group reported
that expression of SESN2 is regulated by the c-Jun NH
(2)-terminal kinase (JNK)/c-Jun pathway in nasopha-
ryngeal carcinoma cell lines CNE1 and CNE2. JNK
has been identified as a regulator of autophagy in cells
exposed to excisanin A or serum deprivation in CNE1
and CNE2 cells. Activation of JNK can cause upregu-
lation of SESN2 expression, which can be blocked
using specific siRNAs that are directed against JNK1/2
or c-Jun. Importantly, silencing expression of SESN2
similarly inhibits induction of autophagy. Moreover,
knockdown of the autophagy-related genes ATG5 or
SESN2 significantly decreases cell death induced by
excisanin A, thereby suggesting that JNK is a novel
mediator of SESN2 expression, which plays a key role
in autophagy induction (Zhang et al. 2013).
Interestingly, SESN2 is also expressed in endothelial
cells and displays a protective function in that it prevents
fibrotic injury in diabetes (Eid et al. 2013). However, the
exact role of SESN2 in the vascular system and endo-
thelial cells is still not clearly understood. In this study,
we investigated the effects of SESN2 on AngII-induced
cytotoxicity in human umbilical vein endothelial cells
(HUVECs). We report that induction of SESN2 can offer
protection against AngII-induced stress in HUVECs.
Materials and methods
Cell culture, treatment, and transfection
Human umbilical vein endothelial cells (HUVECs)
were purchased from Lonza (Walkersville, USA).
Cells were maintained in EBM-2 media plus 20 % fetal
bovine serum (FBS) with supplemental growth factors
according to manufacturer’s instructions (Zhou et al.
2012). AngII (Sigma-Aldrich, USA) was used to treat
HUVECs for various periods of time and with various
doses in an effort to detect alterations in SESN2 expres-
sion in response to AngII treatment. HUVECs were
treated with AngII at concentrations of 0, 0.5, 1, and
2μM for 48 h. In an effort to detect alterations in SESN2
expression in response to administration of AngII in a
time-dependent manner, cells were treated with 1 μM
AngII for 24, 48, and 72 h. The siRNA sequence
targeting SESN2 was designed according to Budanov
et al. 2004. The siRNA sequence targeting both SESN2
(5′-GACCAUGGCUACUCGCUGATT-3′) and a ran-
dom sequence of annealed oligonucleotides (5′-CGUA
CGCGGAAUACUUCGATT-3′) was transfected into
HUVECs using Lipofectamine® RNAiMAX reagent
(Invitrogen) in accordance with the manufacturer’s
instructions.
An upstream fragment (approximately 2,000 bp,
spanning from −2,396 to −214) of SENS2 proximal
promoters was generated by polymerase chain reaction
(PCR) and was subsequently cloned into pGL3.0 firefly
luciferase reporter (Promega, USA) using human geno-
mic DNA extracted from M17 cells (human) as a tem-
plate. The DNA sequences of the constructs were veri-
fied by sequence analysis using an ABI7700 DNA cycle
sequencer. This was done in accordance with the man-
ufacturer’s instructions. The luciferase reporter of
SESN2 was transfected into HUVECs using
Lipofectamine 2000 reagent (Invitrogen) in accordance
with the manufacturer’s instructions. Cells were infected
with either c-Jun-expressing retroviruses (Addgene
plasmid 40348) or control retroviral vector pMIEG3
and were sorted for GFP expression as previously de-
scribed (Wang et al. 2005).
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Measurement of reactive oxygen species
Intracellular ROS in HUVECs was determined by
fluorescence dye 2′, 7′-dichlorfluorescein-diacetate
(DCFH-DA) as described previously (Sheng et al.
2009). Briefly, HUVECs were loaded with 15 μM
DCFH-DA (Sigma, USA) and incubated in darkness
in a CO2 incubator for 45 min at 37 °C. Cells were
then washed three times with 1× phosphate buffered
saline (PBS) and fluorescence signals were recorded
using a fluorescence microscope. The average fluo-
rescence intensity analyzed by Image-Pro Plus soft-
ware (Version 5.0) was calculated and used to reflect
the levels of intracellular ROS.
Measurement of lactate dehydrogenase release
Lactate dehydrogenase (LDH) activity released into
the medium from dead cells was determined with a
commercial LDH cytotoxicity assay kit (Pierce,
USA) using an enzymatic reaction that resulted in
a spectrophotometrically measurable red formazan
product. Briefly, the assay was performed by trans-
ferring cell culture media from treated cells into a
new microplate and adding the kit reagents.
Following incubation at room temperature for
30 min, reactions were stopped and LDH activity
was determined by its spectrophotometric absor-
bance at 490 nm.
Immunofluorescence staining of 4-hydroxy-2-nonenal
Following the completion of each respective exper-
iment, HUVECs were washed and fixed in 4 %
paraformaldehyde for 10 min at RT. Cells were then
permeabilized on ice with 0.4 % Triton X-100 for
15 min. After being blocked with 5 % bovine serum
albumin and 2.5 % fetal bovine serum in PBST,
cells were incubated with the primary antibody
anti-4-hydroxy-2-nonenal (4-HNE; Cell Signaling,
USA) for 1 h at RT followed by incubation with
Alexa-594-conjugated goat anti-mouse secondary
antibodies (Invitrogen, USA) for 30 min. Red fluo-
rescence signals were captured using a fluorescence
microscope. The average fluorescence intensity was
used to reflect the level of 4-HNE as analyzed by
Image-Pro Plus software.
TUNEL assay and DAPI staining
DNA fragmentation resulting from apoptotic signaling
cascades was determined by terminal deoxynucleotidyl
transferase (TUNEL) assay. Briefly, HUVECs were
plated on Lab-Tek® Chamber Slides (Nalgene Nunc,
USA) and cultured in the indicated medium. Following
the indicated transfection and treatment, apoptosis was
assessed and verified using a commercially available kit
(Promega, USA) in accordance with the given protocol.
Nuclei were counterstained with 4′, 6-diamidino-2-
phenylindole (DAPI).
Real-time polymerase chain reaction
Total cellular RNA was isolated from cultured
HUVECs using TRIzol reagent according to the man-
ufacturer’s protocol and then subjected to real-time
quantitative TaqMan PCR analysis in order to mea-
sure the relative levels of SESN2 messenger (m)RNA
expression. Briefly, 2 μg of total cellular RNA was
used for reverse transcription. Synthesized cDNAwas
used to perform real-time PCR in 96-well microtiter
plates with TaqMan reverse transcription reagents
(Applied Biosystems, USA) as previously described
(Shatat et al. 2013). Amplification of the human glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH)
gene was performed in the same reaction on all sam-
ples tested as an internal control for variations in the
amount of RNA. The following primers were used in
this study: SESN2: forward, 5′-CAAGCTCGGAAT
TAATGTGCC-3′; reverse, 5′-CTCACACCATTAAG
CATGGAG-3′. Glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH): forward, 5′-TGTGTCCGTC
GTGGATCTGA- 3′; reverse, 5′-CCTGCTTCACCA
CCTTCTTGA-3′.
Western blot analysis
HUVECs were lysed in cell lysis buffer (Cell Signaling,
USA) supplemented with complete protease inhibitor
and phosphatase inhibitor cocktail (Roche, USA).
Protein concentrations in cell lysates were determined
using a Thermo Scientific Pierce BCA protein assay kit.
The extracted protein was separated using 10 % sodium
dodecyl sulfate polyacrylamide gel electrophoresis
(SDS–PAGE) and electrotransferred to a polyvinylidene
fluoride (PVDF) membrane (Millipore, USA). After
being blocked with 5 % non-fat milk, the membranes
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were incubated with primary antibodies, washed, and
then incubated with peroxidase-conjugated anti-goat
antibodies. The bound antibodies were detected by
chemiluminescence using an ECL detection kit
(Amersham Biosciences, USA). The following antibod-
ies were used in this study: antibodies against sestrin-2
(1:1,000), cleaved caspase 3 (1:500), HO-1 (1:2,000), p-
JNK (1:1,000), p-c-Jun (1:1,000), JNK (1:3,000), and c-
Jun (1:3,000) were obtained from Cell Signaling
Technology, USA; the antibody against β-actin
(1:10,000) was obtained from Santa Cruz
Biotechnology.
Statistical analysis
All quantitative variables are presented as means±SEM.
One-way analysis of variance (ANOVA) was used to
assess the statistical significance of differences among
treatment groups. Interactive effects between pairs were
analyzed using two-way ANOVA. p<0.05 was consid-
ered statistically significant.
Results
Firstly, we investigated the effects of AngII treatment on
SESN2 expression in HUVECs. Cells were incubated
with AngII for various periods of time and at various
doses. Expression of SESN2 at mRNA levels was de-
termined by real-time PCR, and Western blot analysis
was used to determine SESN2 expression at protein
levels. As shown in Fig. 1a, b, at concentrations of 0,
0.5, 1, and 2 μM, 48-h AngII treatment on HUVECs led
to a sustainable increase in messenger RNA (mRNA)
and protein levels of SESN2. Moreover, HUVECs were
incubated with 1 μM AngII for various periods of time
ranging from 24 to 72 h. The results showed a sustain-
able increase of SESN2 at both mRNA levels (Fig. 1c)
and protein levels in a time-dependent manner (Fig. 1d).
The increased levels of SESN2 suggest a potential role
of SESN2 in the treatment of HUVECs suffering from
AngII insults. In addition, we investigated the expres-
sion of the canonical oxidative stress response gene HO-
1. Our results indicate that treatment with AngII in
HUVECs leads to a significant increase in HO-1 expres-
sion (Fig. 1e), which is consistent with previous findings
(Mai et al. 2014).
With further investigation, we studied the roles of
SESN2 in AngII insults. The effects of SESN2 in AngII
cytotoxicity were examined through inhibition of
SESN2 using SESN2 small RNA interference in
HUVECs. Our results indicate that transfection with
siSESN2 downregulates expression of SESN2 in both
control and AngII-treated cells (Fig. 2).
Cell viability was determined by MTT assay. As is
shown in Fig. 3a, MTT assay results show that knock-
down of SESN2 exacerbates the impaired cell viability
induced by 1 μM AngII treatment for 48 h. To confirm
that inhibition of SESN2 increases cell vulnerability to
AngII, levels of cellular toxicity were determined using
an LDH assay. Consistently, knockdown of SESN2 in
HUVECs exacerbated AngII-induced LDH release after
48 h incubation (Fig. 3b). Oxidative stress plays an
essential role in the process of AngII-induced cytotox-
icity. Thus, oxidative stress patterns were investigated
by measuring the levels of ROS and 4-HNE after AngII
incubation and SESN2 knockdown. The results indicate
that knockdown of siSESN2 significantly increases
levels of ROS and 4-HNE, which is consistent with a
previous study that shows that elevated ROS levels can
be found in SESN2 knockout (−/−) sensory neurons
(Kallenborn-Gerhardt et al. 2013). Importantly, our re-
sults also show that inhibition of SESN2 exacerbates the
increase in levels of ROS (Fig. 4a) and 4-HNE (Fig. 4b)
induced by AngII treatment.
AngII has also been shown to induce apoptosis in
multiple cell lines. In order to determine whether
SESN2 has a direct effect on apoptosis, TUNEL stain-
ing was used for apoptosis detection following SESN2
knockdown and AngII treatment. As is shown in Fig. 5,
inhibition of SESN2 significantly promotes apoptosis in
HUVECs induced by AngII treatment. Caspase 3 is a
critical executioner of apoptosis. Our results indicate
that inhibition of SESN2 exacerbates the effects of
AngII on the activation of caspase 3 (Fig. 6).
Different forms of stress have been shown to mediate
c-Jun NH (2)-terminal kinase (JNK) activation via var-
ious cellular pathways. JNK activation in response to
AngII has been reported to participate in regulating
apoptosis (Hu et al. 2006). Therefore, we speculated
that JNK participates in the induction of SESN2 induced
by AngII treatment. In order to examine whether JNK/c-
Jun mediates AngII-induced induction of SESN2, ex-
pression patterns of JNK and c-Jun were investigated in
HUVECs. JNK phosphorylates the transcriptional factor
c-Jun on Ser-63 and Ser-73, thereby increasing its tran-
scriptional potential. Indeed, our results indicate that
exposure to AngII significantly increases phospho-c-
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Fig. 1 AngII treatment increased the expression of sestrin-2
(SESN2) in human umbilical vein endothelial cells (HUVECs). a
HUVECswere stimulatedwith AngII at various concentrations for
48 h. mRNA levels of SESN2 at various concentrations were
determined by real-time PCR (*p<0.01 vs. non-treated control);
b Protein levels of SESN2 at various concentrations were deter-
mined byWestern blot analysis (*p<0.01 vs. non-treated control);
c HUVECs were stimulated with AngII at indicated doses (1 μM)
for varying periods of time. mRNA levels of SESN2 at varying
time periods were determined by real-time PCR (*p<0.01 vs. non-
treated control); d Protein levels of SESN2 at varying time periods
were determined by Western blot analysis (*p<0.01 vs. non-
treated control); e Protein levels of HO-1 at varying time periods
were determined by Western blot analysis (*p<0.01 vs. non-
treated control)
Fig. 2 Western blot analysis revealed the successful knockdown of SESN2 in both control and AngII-treated cells (*p<0.01 vs NS control;
#p<0.01 vs NS+AngII group); NS non-specific RNA, siSESN2 sestrin-2 small RNA interference
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Jun as well as phospho-JNK (Fig. 7a). However, total
levels of c-Jun and JNK did not undergo any changes. In
order to verify whether activated c-Jun is involved in
AngII-induced induction of SESN2 expression,
HUVECs were treated with 25 nM of JNK inhibitor
SP600125. Interestingly, we found that AngII-induced
upregulation of SESN2 expression is blunted by
SP600125 (Fig. 7b), thereby indicating that AngII-
induced SESN2 expression is mediated by activation
of the JNK/c-Jun signaling pathway.
In order to understand how c-Jun regulates SESN2,
we set out to detect its effects on the promoter activity of
SESN2. A strong transactivation effect on the SESN2
promoter took place after cells were infected with retro-
viruses containing c-Jun and is shown in Fig. 8a.
Consistently, overexpression of retroviral c-Jun induced
Fig. 3 Inhibition of Sestrin-2 (SESN2) exacerbated cell death
induced by AngII in human umbilical vein endothelial cells
(HUVECs). NS non-specific RNA, siSESN2 sestrin-2 small
RNA interference. a After incubation with 1 μM AngII for 48 h,
MTT assay results revealed that SESN2-knocked down cells were
more vulnerable to AngII-induced cytotoxicity (*p<0.01 vs NS
group; #p<0.01 vs NS+(AngII) group); b After incubation with
1 μM AngII for 48 h, LDH assay results revealed that SESN2-
knocked down cells showed recued resistibility to AngII-induced
cell death (*p<0.01 vs NS group; #p<0.01 vs NS+(AngII) group)
Fig. 4 Inhibition of Sestrin-2 (SESN2) exacerbated oxidative
stress induced by AngII in human umbilical vein endothelial cells
(HUVECs). NS non-specific RNA, siSESN2 sestrin-2 small RNA
interference. a After incubation with 1 μM AngII for 48 h,
SESN2-knocked down HUVECs showed more intracellular
ROS accumulation than non-specific siRNA-transfected control
(*p<0.01 vs NS group; #p<0.01 vs NS+(AngII) group); b After
incubation with 1 μM AngII for 48 h, SESN2-knocked down
HUVECs exhibited a significant increase of 4-HNE (*p<0.01 vs
NS group; #p<0.01 vs NS+(AngII) group)
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expression of SESN2 at bothmRNA levels (Fig. 8b) and
protein levels (Fig. 8c). Notably, AngII treatment led to
a significant increase in the SESN2 luciferase reporter
(Fig. 9). Taken together, our findings indicate that AngII
treatment in HUVECs might significantly induce
SESN2 expression through a mechanism(s) involving
the activation of the JNK/c-Jun pathway. A schematic
representation of the underlying mechanism is shown in
Fig. 10.
Discussion
SESN2 is a member of the sestrin family of PA26-
related proteins. The encoded protein may function in
the regulation of cell growth and survival (Lee et al.
2010). This protein may be involved in cellular re-
sponses to different stress conditions and is able to
maintain redox homeostasis. However, its mode of
action has yet to be elucidated. Under normal condi-
tions, expression of SESN2 is found to take place in
endothelial cells; however, alterations in SESN2 ex-
pression in the process of endothelial dysfunction are
not yet understood. The present study demonstrates
that induction of SESN2 mediated by JNK/C-Jun in
HUVECs might act as a compensatory response for
cell survival when cells are subjected to AngII insults.
In this investigation, we first detected the expression
of SESN2 in HUVECs and found that SESN2 levels
are increased by AngII in both a time-dependent and a
Fig. 5 Inhibition of SESN2 expression exacerbated AngII-in-
duced HUVECs apoptosis. NS non-specific RNA, siSESN2
sestrin2 small RNA interference. HUVECs were transfected with
siSESN2 and treated with AngII for 48 h and stained using a
TUNEL assay kit. Nuclear DNA was stained with DAPI
(*p<0.01 vs. NS group; #p<0.01 vs. NS+(AngII) group)
Fig. 6 Western blot analysis revealed that SESN2 silence promoted the effects of AngII on activation of caspase 3. NS non-specific RNA,
siSESN2 sestrin2 small RNA interference (*p<0.01 vs. NS group; #p<0.01 vs. NS+(AngII) group)
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dose-dependent manner. Inhibition of SESN2 by
small RNA interference promoted cytotoxicity of
AngII in that it increased cell vulnerability, oxidative
stress, and apoptosis. Importantly, we found that
AngII treatment in HUVECs might significantly in-
duce SESN2 expression through a mechanism(s) in-
volving the activation of the JNK/c-Jun pathway.
It has been well documented that the renin–angioten-
sin system (RAS) plays a major role in the pathogenesis
of cardiovascular diseases (Rosenbaugh et al. 2013). As
the main effector peptide of the RAS, AngII is known to
be involved in the regulation of cardiac contractility, cell
communication, and impulse propagation (Xue et al.
2012). Importantly, AngII is able to induce apoptosis
Fig. 7 JNK/c-Jun mediates AngII-induced upregulation of
SESN2. aHUVECswere treated with AngII for 48 h. Immunoblot
and quantification analysis revealed that the levels of p-JNK and p-
c-Jun are increased by AngII (*p<0.01 vs. non-treated control; n=
4). b HUVECs were treated with AngII with or without the
presence of 25 nM of JNK inhibitor SP600125 for 48 h. Western
blot analysis revealed that the induction of SESN2 by AngII were
blunt by JNK inhibitor SP600125 (*p<0.01 vs. control group;
#p<0.01 vs. AngII-treated group)
Fig. 8 Overexpression of retroviral c-Jun promotes the expression
of SESN2. a c-Jun stimulates the promoter activity of SESN2.
Activity of SESN2 promoter was measured after the overexpres-
sion of retroviral c-Jun; normalized (firefly/protein concentration)
promoter activity is expressed relative to vector control; b Real-
time PCR results verified that overexpression of retroviral c-Jun
increased the expression of c-Jun at the mRNA levels; c Western
blot analysis revealed that overexpression of retroviral c-Jun in-
creased the expression of c-Jun at the protein levels (*p <0.01 vs.
vector control, n=4–5)
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via activation of specific AngII receptors (Wolf 2005).
Multiple lines of evidence demonstrate that activation of
AngII signaling triggers pro-inflammatory effects as well
as production of reactive oxygen species (ROS) in the
vascular wall by inducing multiple downstream path-
ways, which consequently causes endothelial dysfunc-
tion and cardiovascular disease (Brasier et al. 2002).
The JNK pathway can be activated by various stress-
or signals such as cytokines and oxidative stress.
Activation of JNK has been implicated in the cytotox-
icity of AngII (Alves et al. 2012). Importantly, activation
of JNK has been reported to play an important role in the
pathogenesis of cardiovascular and metabolic diseases
(Zhou et al. 2010). In this study, we report that activation
of JNK/c-Jun mediates induction of SESN2, which ex-
pands our understanding of the role of JNK in AngII-
mediated cytotoxicity. Overexpression of c-Jun pro-
motes activity of the SESN2 promoter luciferase, sug-
gesting that the effects of AngII on the induction of
SESN2 take place at the transcriptional level. Expression
of SESN2 is induced in response to DNA damage and
oxidative stress. SESNs act as modulators of cellular
hydrogen peroxide concentration. Hydrogen peroxide
is an important signaling molecule that is strictly
regulated. The induction of SESN2 might have
cytoprotective activity against various stresses such
as hydrogen peroxide or ischemia based on regenera-
tion of overoxidized peroxiredoxins (PRXs) through
its reductase activity toward cysteine sulfinic acid of
peroxiredoxin (Shin et al. 2012; Budanov et al. 2002,
2004. PRXs are able to maintain the cellular reducing
environment by scavenging intracellular hydrogen
peroxide (Brinkmann and Brixius 2013). In addition
to inhibiting ROS accumulation through maintenance
of PRXs activity, SESN2 also performs other antiox-
idant mechanisms of action (Sanchis-Gomar 2013).
Moreover, it has been reported that SESNs activate
AMP-activated protein kinase (AMPK) and suppress
mammalian target of rapamycin complex 1 (mTORC1)
and p70 S6 kinase (S6K) (mTORC1-S6K) activity. A
recent study demonstrates that SESN2 ablation exacer-
bates obesity-induced mTORC1-S6K activation, glucose
intolerance, insulin resistance, and hepatosteatosis; all of
which are reversed by AMPK activation, suggesting that
SESN2 exerts in addition to important homeostatic func-
tions in the control of mammalian lipid and glucose
metabolism (Lee et al. 2012a). Importantly, SESN2-
dependent AMP-activated protein kinase (AMPK) acti-
vation has been reported to attenuate high glucose-
induced glomerular mesangial cell fibronectin synthesis
through blockade of NADPH oxidase 4 (Nox4)-depen-
dent ROS and peroxynitrite generation, with subsequent
endothelial nitric oxide synthase (eNOS) uncoupling
(Eid et al. 2013), suggesting a protective function for
sestrin-2/AMPK and potential targets for intervention to
prevent fibrotic injury in diabetes.
In this study, AngII treatment was able to upregulate
expression of SESN2. Furthermore, inhibition of
SESN2 expression exacerbated AngII toxicity. These
findings suggest that induction of SESN2 might have a
protective effect on AngII toxicity. Continuing efforts
are being made to understand the mechanisms through
which AngII acts as a mediator of endothelial apoptosis.
Prevention of AngII toxicity has become an important
potential target for treatment of cardiovascular diseases.
Our study implies that stimulating expression of SESN2
might be an effective pharmacological target for treat-
ment of AngII-associated cardiovascular diseases.
Fig. 9 AngII treatment stimulates the promoter activity of
SESN2. Activity of SESN2 promoter was measured after 1 μM
AngII treatment. Normalized (firefly/protein concentration) pro-
moter activity is expressed relative to vector control
Fig. 10 Schematic drawing of the effects of AngII on SESN2
induction
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